Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Carparts.Com Inc (PRTS) Price & Performance

Heron Therapeutics IncTrade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Carparts.Com Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Carparts.Com Inc trades at $8.63 (market cap $66.42M). The key difference: Heron Therapeutics Inc and Carparts.Com Inc are close in size by market cap, and Carparts.Com Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Carparts.Com Inc for 45 Days on average.

HRTXPRTS
Market Cap
$68.01M$66.42M
Volume
1,891,94140,287
Sector
HealthConsumer Cyclical
52-Week High
$1.49$10.00
52-Week Low
$0.27$3.88
Typical Hold Time
35 Days45 Days
Enterprise Value
$174.75M$79.39M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.

The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.

Carparts.Com Inc

CarParts.com (PRTS) trades at $8.64, down 0.63% on the day, with a bullish technical signal from moving averages. The company shows improving quarterly earnings performance, beating estimates for three consecutive quarters despite negative net income margins. Revenue has declined from $676M in 2023 to $548M in 2025, but recent news highlights the company's focus on leveraging proprietary data to build competitive advantages in the automotive e-commerce space.

While analyst sentiment remains positive with 60% buy ratings, the stock faces fundamental challenges including declining revenue, negative profitability metrics, and negative operating cash flow. The primary investment opportunity lies in the company's improving earnings trajectory and data-driven strategy, balanced against execution risks in a competitive market and ongoing profitability concerns.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRTX
43% Buy57% Sell
Avg holding period · 35 Days
PRTS
0% Buy100% Sell
Avg holding period · 45 Days

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS →